Jerusalem-based drugmaker Teva Pharmaceutical (NASDAQ:TEVA) reported Q2 EPS of $1.08, topping consensus estimates of $1.04.
Revenues in the quarter rose 12% to $3.8 billion, inline with consensus estimates.
The company highlighted its outperformance in the North America region, where it unveiled nine new products during the second-quarter.
Link to this comment:
All Comments (0)